Innate Pharma updates on it next meetings with analysts and investors
Innate Pharma reports today its consolidated financial results for the year ending December 31, 2009 and updates on its drug candidates
Innate Pharma reports operating revenue of 7.7 million euros for 2009
Number of shares and voting rights and cash situation of INNATE PHARMA as at December 31, 2009
Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES
Innate Pharma announces its financial and investor relations calendar for 2010 and the settlement and delivery of its capital increase
Innate Pharma announces today a capital increase of a maximum of 24.3 million euros reserved to categories of investors
New data presented at the Annual Meeting of the American Society of Hematology (“ASH”)
Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma
Innate Pharma SA announces its turnover for the third quarter of 2009 and updates on its cash situation
